414 related articles for article (PubMed ID: 33387670)
1. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants.
Liu Z; Suo C; Shi O; Lin C; Zhao R; Yuan H; Jin L; Zhang T; Chen X
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e855-e875. PubMed ID: 33387670
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
[TBL] [Abstract][Full Text] [Related]
3. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants.
Chen S; Pang J; Huang R; Xue H; Chen X
Hepatol Int; 2023 Jun; 17(3):595-605. PubMed ID: 36809487
[TBL] [Abstract][Full Text] [Related]
4. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
Lin YC; Chang PF; Chang MH; Ni YH
Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
[TBL] [Abstract][Full Text] [Related]
8. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.
Zusi C; Mantovani A; Olivieri F; Morandi A; Corradi M; Miraglia Del Giudice E; Dauriz M; Valenti L; Byrne CD; Targher G; Maffeis C
Dig Liver Dis; 2019 Nov; 51(11):1586-1592. PubMed ID: 31255630
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
[TBL] [Abstract][Full Text] [Related]
10. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
[TBL] [Abstract][Full Text] [Related]
12. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study).
Käräjämäki AJ; Hukkanen J; Kauma H; Kesäniemi YA; Ukkola O
Scand J Clin Lab Invest; 2020; 80(2):106-113. PubMed ID: 31851849
[TBL] [Abstract][Full Text] [Related]
14. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review.
Ismaiel A; Dumitrascu DL
Eur J Clin Invest; 2020 Oct; 50(10):e13331. PubMed ID: 32589269
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis.
Fan H; Liu Z; Zhang P; Wu S; Han X; Huang Y; Zhu Y; Chen X; Zhang T
Hepatol Int; 2023 Jun; 17(3):615-625. PubMed ID: 37000387
[TBL] [Abstract][Full Text] [Related]
16. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
[TBL] [Abstract][Full Text] [Related]
17. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
[TBL] [Abstract][Full Text] [Related]
18. NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study.
Xia M; Ma S; Huang Q; Zeng H; Ge J; Xu W; Wu Q; Wu L; Li X; Ma H; Chen L; Li Q; Aleteng Q; Hu Y; He W; Pan B; Lin H; Zheng Y; Wang S; Tang H; Gao X
Aliment Pharmacol Ther; 2022 Mar; 55(6):705-721. PubMed ID: 35023183
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children.
Di Costanzo A; Pacifico L; D'Erasmo L; Polito L; Martino MD; Perla FM; Iezzi L; Chiesa C; Arca M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31505904
[No Abstract] [Full Text] [Related]
20. Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan.
Raja AM; Ciociola E; Ahmad IN; Dar FS; Naqvi SMS; Moaeen-Ud-Din M; Kaukab Raja G; Romeo S; Mancina RM
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]